CATCH: Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05502874
Collaborator
(none)
1,600
1
37
43.3

Study Details

Study Description

Brief Summary

This multicenter observational study will explore the risk factors of early neurological deterioration(END) in patients with primary and to investigate the association between END and outcome.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Neurological deterioration affects approximately one-third of patients with primary intracerebral hemorrhage (ICH) and increases the risk of death and dependency. However, the risk factors of early neurological deterioration (END), such as biochemical parameters, neuroimaging, and systemic complications, are not well documented in primary ICH, and the effective predictors of END is unknown.

    This multicenter observational study aims to seek out the risk factors of END in patients with primary ICH and to investigate the association between END and outcome.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1600 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
    Anticipated Study Start Date :
    Sep 1, 2022
    Anticipated Primary Completion Date :
    Dec 1, 2024
    Anticipated Study Completion Date :
    Oct 1, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Early neurological deterioration (END) [48 hours after admission]

      END is defined as an increase in the total NIHSS score of ≥ 4 points within the first 48 h after admission

    Secondary Outcome Measures

    1. Late neurological deterioration (LND) [7 days]

      LND is defined as an increase in the total NIHSS score of ≥ 4 points between 48h and 7 days after admission

    2. Functional outcome [90 days, 1 year, 2 years after admission]

      Functional outcome will be assessed with modified ranking scale(mRS).Poor outcome is defined as mRS 4-6 at follow-up

    3. Hematoma expansion [24 hours after admission]

      Hematoma volume expansion of at least 6 mL or 33% on a CT scan obtained 24 hours after admission compared with the entry scan.

    4. The quality of life [90 days, 1 year, 2 years after admission]

      The quality of life will be assessed with the EuroQol-5D (EQ-5D) scale.

    5. Depression status [90 days, 1 year, 2 years after admission]

      Patient Health Questionnaire (PHQ)-9 scale will be evaluated, and higher scores means a worse status.

    6. Cognitive function [90 days, 1 year, 2 years after admission]

      Telephone Interview for Cognitive Status-Modified(TICS-m) scale will be evaluated via telephone interview.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Confirmed diagnosis of primary intracerebral hemorrhage
    Exclusion Criteria:
    • Patients with secondary

    • Undergo surgical evacuation of hematoma;

    • Presenting contraindications or refusal to MRI

    • Is pregnant

    • Patients refuse to be followed up for any reasons.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 2nd Affiliated Hospital, School of Medicine at Zhejiang University Hangzhou Zhejiang China 310000

    Sponsors and Collaborators

    • Second Affiliated Hospital, School of Medicine, Zhejiang University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Second Affiliated Hospital, School of Medicine, Zhejiang University
    ClinicalTrials.gov Identifier:
    NCT05502874
    Other Study ID Numbers:
    • 08268522
    First Posted:
    Aug 16, 2022
    Last Update Posted:
    Aug 16, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Second Affiliated Hospital, School of Medicine, Zhejiang University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 16, 2022